Codon-optimization of the hemagglutinin gene from the novel swine origin H1N1 influenza virus has differential effects on CD4+ T-cell responses and immune effector mechanisms following DNA electroporation in mice

Vaccine

Volumn 28, Issue 19, 2010, Pages 3273-3277

  Tenbusch, M ^a   Grunwald, T ^a   Niezold, T ^a   Bonsmann, M Storcksdieck genannt ^a   Hannaman, D ^b   Norley, S ^c   Uberla K ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Ichor Medical Systems Inc   (United States)

^c ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Codon optimization; DNA electroporation; Swine flu; Vaccination

Indexed keywords

DNA VACCINE; HEMAGGLUTININ; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CODON; CONTROLLED STUDY; DNA IMMUNIZATION; ELECTROPORATION; FEMALE; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VIRUS A H1N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SWINE; SWINE INFLUENZA; WILD TYPE;

ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CODON; ELECTROPORATION; FEMALE; HEMAGGLUTININS, VIRAL; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; PLASMIDS; VACCINES, DNA;

EID: 77950519577     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.02.090     Document Type: Article

References (26)

1. Jones S., Evans K., Elwaine-Johnn H., Sharpe M., Oxford J., Lambkin-Williams R., et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 27 April (18) (2009) 2506-2512
2. Bachy M., Boudet F., Bureau M., Girerd-Chambaz Y., Wils P., Sherman D., et al. Electric pulses increase the immunogenicity of an influenza DNA vaccine injected intramuscularly in the mouse. Vaccine 19 February (13-14) (2001) 1688-1693
3. Liu J., Kjeken R., Mathiesen I., and Barouch D.H. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J Virol 82 June (11) (2008) 5643-5649
4. Widera G., Austin M., Rabussay D., Goldbeck C., Barnett S.W., Chen M., et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 164 May (9) (2000) 4635-4640
5. Luckay A., Sidhu M.K., Kjeken R., Megati S., Chong S.Y., Roopchand V., et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 81 May (10) (2007) 5257-5269
6. Capone S., Zampaglione I., Vitelli A., Pezzanera M., Kierstead L., Burns J., et al. Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. J Immunol 177 November (10) (2006) 7462-7471
7. Vasan S., Hurley A., Schlesinger S.J., Hannaman D., Gardiner D.F., Dugin D.P., et al. OA05-01. In vivo electroporation enhances the immunogenicity of ADVAX, a DNA-based HIV-1 vaccine candidate, in healthy volunteers. Retrovirology 6 Suppl. 3 (2009) O31
8. Zheng L., Wang F., Yang Z., Chen J., Chang H., and Chen Z. A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice. BMC Infect Dis 9 1 (2009) 17
9. Deml L., Bojak A., Steck S., Graf M., Wild J., Schirmbeck R., et al. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 gag protein. J Virol 75 November (22) (2001) 10991-11001
10. Seo S.H., Jin H.T., Park S.H., Youn J.I., and Sung Y.C. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Vaccine 27 September (42) (2009) 5906-5912
11. Smith J.M., Rao Amara R., Campbell D., Xu Y., Patel M., Sharma S., et al. DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. AIDS Res Hum Retroviruses 20 December (12) (2004) 1335-1347
12. Kohlmann R., Schwannecke S., Tippler B., Ternette N., Temchura V.V., Tenbusch M., et al. Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus. J Virol 83 December (23) (2009) 12601-12610
13. Ternette N., Stefanou D., Kuate S., Uberla K., and Grunwald T. Expression of RNA virus proteins by RNA polymerase II dependent expression plasmids is hindered at multiple steps. Virol J 4 (2007) 51
14. Simabuco F.M., Tamura R.E., Carromeu C., Farinha-Arcieri L.E., and Ventura A.M. Gene optimization leads to robust expression of human respiratory syncytial virus nucleoprotein and phosphoprotein in human cells and induction of humoral immunity in mice. J Virol Methods 158 June (1-2) (2009) 93-99
15. Ternette N., Tippler B., Uberla K., and Grunwald T. Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus. Vaccine 10 October (41) (2007) 7271-7279
16. Fouchier R.A., Meyer B.E., Simon J.H., Fischer U., and Malim M.H. HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. EMBO J 16 (1997) 4531-4539
17. Luxembourg A., Hannaman D., Ellefsen B., Nakamura G., and Bernard R. Enhancement of immune responses to an HBV DNA vaccine by electroporation. Vaccine 24 May (21) (2006) 4490-4493
18. Aricescu A.R., Lu W., and Jones E.Y. A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr D: Biol Crystallogr 62 October (Pt 10) (2006) 1243-1250
19. Park S.H., Cheong C., Idoyaga J., Kim J.Y., Choi J.H., Do Y., et al. Generation and application of new rat monoclonal antibodies against synthetic FLAG and OLLAS tags for improved immunodetection. J Immunol Methods 331 February (1-2) (2008) 27-38
20. Robinson H.L., Boyle C.A., Feltquate D.M., Morin M.J., Santoro J.C., and Webster R.G. DNA immunization for influenza virus: studies using hemagglutinin- and nucleoprotein-expressing DNAs. J Infect Dis 176 August (s1) (1997) S50-S55
21. Jiang Y., Yu K., Zhang H., Zhang P., Li C., Tian G., et al. Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector. Antiviral Res 75 September (3) (2007) 234-241
22. Pantaleo G., and Koup R.A. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 10 August (8) (2004) 806-810
23. Seder R.A., Darrah P.A., and Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8 April (4) (2008) 247-258
24. Siegismund C.S., Hohn O., Kurth R., and Norley S. Enhanced T- and B-cell responses to simian immunodeficiency virus (SIV)agm, SIVmac and human immunodeficiency virus type 1 Gag DNA immunization and identification of novel T-cell epitopes in mice via codon optimization. J Gen Virol 90 October (10) (2009) 2513-2518
25. Szécsi J., Gabriel G., Edfeldt G., Michelet M., Klenk H.-D., and Cosset F.L. DNA vaccination with a single-plasmid construct coding for viruslike particles protects mice against infection with a highly pathogenic avian influenza A virus. J Infect Dis 200 July (2) (2009) 181-190
26. Price G.E., Soboleski M.R., Lo C.Y., Misplon J.A., Pappas C., Houser K.V., et al. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 27 November (47) (2009) 6512-6521